| Use of Dolutegravir in Individuals of Childbearing Capacity Lead author: Geoffrey A. Weinberg, MD, with the MCCC, updated May 2021 |
| Evidence from multiple studies indicates no difference in rates of total birth defects among infants exposed to antiretroviral (ARV) medications during the first trimester compared with infants exposed later in pregnancy. ARVs are generally considered safe and may be taken by pregnant patients with HIV without increasing the risk of infant birth defects. The MCCC is providing the following updated information for medical care providers concerning preliminary reports that previously had linked dolutegravir (DTG) to neural tube defects (NTDs) in infants exposed to dolutegravir during the periconception period [Zash, et al. 2018; Zash, et al. 2019; Reefhuis, et al. 2020]. Read the full statement. |
Skip to content
NEW YORK STATE DEPARTMENT OF HEALTH AIDS INSTITUTE See Our Statement on Inclusive Care
